Lomerizine is a diphenylpiperazine-class calcium channel blocker primarily utilized for the clinical treatment of migraines, with ongoing research exploring its potential application for glaucoma and optic… Read more
Lomerizine is a diphenylpiperazine-class calcium channel blocker primarily utilized for the clinical treatment of migraines, with ongoing research exploring its potential application for glaucoma and optic nerve injury. To support rigorous pharmaceutical development, this category provides high-quality reference standards of Lomerizine active pharmaceutical ingredients, alongside its specific impurities and stable isotope-labelled compounds. Pharmaceutical and research laboratories rely on these materials for critical analytical testing, including impurity profiling, method validation, and quantitative analysis. By using these certified reference materials, scientists can ensure accurate identification and quantification of degradation products or synthetic by-products during stability studies and quality control processes. The availability of deuterated Lomerizine analogues further facilitates precise mass spectrometry-based assays, allowing for reliable pharmacokinetic monitoring and the development of robust analytical procedures for this calcium channel blocking agent.